Free Submission Public Relations &
Deutsch English


New Medtronic Deep Brain Stimulation System the First to Sense and Record Brain Activity While Delivering Therapy

Print article Print article
Copyright © Thomson Reuters 2013. All rights reserved.
2013-08-07 15:02:03 -

First Implant of Activa(® )PC+S Deep Brain Stimulation System Initiates Research
   That Could One Day Significantly Change How Neurological and Psychological
                              Diseases are Treated

MINNEAPOLIS AND MUNICH - August 7, 2013 - Medtronic, Inc. (NYSE: MDT) today
announced the first implant of a novel deep brain stimulation (DBS) system that,
for the first time, enables the sensing and recording of select brain activity
while simultaneously providing targeted DBS therapy. This initiates research on
how the brain responds to the therapy and could yield insights that one day
significantly change the way people with devastating neurological 
and psychological disorders, such as Parkinson's disease, essential tremor, dystonia, and treatment-resistant obsessive-compulsive disorder, are treated. The Activa(®) PC+S DBS system delivers proven Medtronic DBS Therapy while at the same time sensing and recording electrical activity in key areas of the brain using sensing technology and an adjustable algorithm, which enable the system to gather brain signals at various moments as selected by a physician.  Initially, this new technology will be made available to a select group of physicians worldwide for use in clinical studies. These physicians will use the system to map the brain's responses to Medtronic DBS Therapy and explore applications for the therapy across a range of neurological and psychological conditions. The Activa PC+S system, which delivers stimulation to targeted areas of the brain like existing Medtronic DBS systems, was implanted for the first time at Ludwig Maximilians University in Munich, Germany in a person with Parkinson's disease. This patient will be treated by a team that includes neurologist Kai Bötzel, department of neurology, Ludwig Maximilian University and neurosurgeon Jan Mehrkens, M.D., head of functional neurosurgery, Ludwig Maximilian University, who implanted the system. Dr. Bötzel will be the first to use data gathered by the Activa PC+S system to gain unprecedented insight into how the brain responds to DBS therapy. "DBS therapy works for people with Parkinson's disease and other movement disorders, but there is much to learn about how the brain responds to the therapy," said Dr. Bötzel. "This new system will allow us to treat patients with conventional DBS therapy, while at the same time opening the door for research that was not possible until now. We hope these insights will lead to the development of effective new treatments tailored to the needs of individuals." "Devastating conditions like Parkinson's disease and obsessive-compulsive disorder take a significant toll on countless people, as well as their loved ones," said Lothar Krinke, Ph.D., vice president and general manager of the Deep Brain Stimulation business in Medtronic's Neuromodulation division. "Medtronic is excited to provide this new system to researchers worldwide, and we expect that their respective studies will lead to accelerated understanding of how neurological and psychological conditions develop and progress. This represents a significant milestone for DBS therapy and the long-term journey toward a closed-loop DBS system, which could personalize therapy by using device data to automatically adjust to the needs of individual patients." Medtronic's Activa PC+S system received CE (Conformité Européenne) mark in January 2013. It is not approved by the U.S. Food and Drug Administration for commercial use in the United States, and will be made available to select physicians for investigational use only. Additional implants of the Activa PC+S system, including the first implant in the United States, will take place in the coming months. Multimedia Release A multimedia version of this release, with links to graphics, animation and additional background information can be found at: About Medtronic DBS Therapy DBS therapy uses a surgically implanted medical device, similar to a pacemaker, to deliver mild electrical pulses to precisely targeted areas of the brain. The stimulation can be programmed and adjusted non-invasively by a trained clinician to maximize symptom control and minimize side effects. More than 100,000 patients worldwide have received Medtronic DBS Therapy. The therapy is currently approved in many locations around the world, including Europe and the United States, for the treatment of the disabling symptoms of essential tremor, advanced Parkinson's disease and chronic intractable primary dystonia, for which approval in the United States is under a Humanitarian Device Exemption (HDE). In Europe, Canada and Australia, DBS therapy is approved for the treatment of refractory epilepsy. DBS therapy is also approved for the treatment of severe, treatment-resistant obsessive-compulsive disorder in the European Union and Australia, and in the United States under an HDE. Medtronic's Leadership in Neuromodulation Medtronic developed and leads the field of neuromodulation, the targeted and regulated delivery of electrical pulses and pharmaceuticals to specific sites in the nervous system. The company's Neuromodulation business includes implantable neurostimulation and targeted drug delivery systems for the management of chronic pain, common movement disorders, spasticity and urologic and gastrointestinal disorders. About Medtronic Medtronic, Inc. (, headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world. Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results. ### Contacts: Justin Ihle Public Relations +1-763-526-0911 Yvan Deurbroeck Media Relations +41 21 802 75 746 Jeff Warren Investor Relations +1-763-505-2696 This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Medtronic, Inc. via Thomson Reuters ONE [HUG#1721051]

Press Information:

Contact Person:

Disclaimer: © 2014 Thomson Reuters. The press releases or report contained herein is protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Thomson Reuters's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact